MannKind Corporation (MNKD) : Mizuho Securities Usa reduced its stake in MannKind Corporation by 43.65% during the most recent quarter end. The investment management company now holds a total of 33,300 shares of MannKind Corporation which is valued at $53,613 after selling 25,800 shares in MannKind Corporation , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.MannKind Corporation makes up approximately 0.01% of Mizuho Securities Usa’s portfolio.
MannKind Corporation closed down -0.09 points or -5.56% at $1.53 with 34,16,203 shares getting traded on Wednesday. Post opening the session at $1.48, the shares hit an intraday low of $1.45 and an intraday high of $1.55 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Atria Investments reduced its stake in MNKD by selling 2,415 shares or 19.45% in the most recent quarter. The Hedge Fund company now holds 10,000 shares of MNKD which is valued at $16,100. Horizon Kinetics sold out all of its stake in MNKD during the most recent quarter. The investment firm sold 380,440 shares of MNKD which is valued $623,922. Capital Investment Advisors added MNKD to its portfolio by purchasing 10,000 company shares during the most recent quarter which is valued at $16,400. Simplex Trading added MNKD to its portfolio by purchasing 11 company shares during the most recent quarter which is valued at $18.
On the company’s financial health, MannKind Corporation reported $-0.66 EPS for the quarter, missing the analyst consensus estimate by $ -0.61 based on the information available during the earnings call on Mar 14, 2016. Analyst had a consensus of $-0.05.Analysts expectations of $ .35.During the same quarter in the previous year, the company posted $-0.09 EPS.
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s product candidate is AFREZZA inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company’s Technosphere powders are -based on the Company’s fumaryl diketopiperazine (FDKP) which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury Connecticut facility.